news
/
Media Statements
Media Statements
Feb 11, 2026
Regeneron Provides Update on Patent Litigation Against Samsung
Dec 02, 2025
Regeneron Provides Update Regarding Catalent Indiana, LLC
Oct 20, 2025
Regeneron Provides Update on Patent Litigation Against Celltrion
Oct 13, 2025
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Regulatory Applications Under Review by the FDA
Sep 29, 2025
Regeneron Provides Update on Patent Litigation Against Formycon
Sep 08, 2025
Regeneron Provides Update on Patent Litigation Against Sandoz
Apr 14, 2025
Regeneron Provides Update on Patent Litigation Against Biocon
Apr 15, 2024
Statement on Department of Justice Filing Related to EYLEA® (aflibercept) Injection 2 mg
Aug 18, 2023
Information for EYLEA HD (aflibercept) Injection 8 mg U.S. List Price
Jan 09, 2023
FDA Advisory Committee Provides Guidance on EYLEA® (aflibercept) Injection as a New Treatment for Preterm Infants with Retinopathy of Prematurity (ROP)
Jan 24, 2022
U.S. Food and Drug Administration Revises Emergency Use Authorization for REGEN-COV® (casirivimab and imdevimab) Antibody Cocktail due to Omicron Variant
Dec 16, 2021
Regeneron’s Next Generation Monoclonal Antibodies are Active Against All Known Variants of Concern, Including Both Omicron and Delta
Nov 30, 2021
Regeneron Evaluating REGEN-COV® and Next Generation Antibodies against New Omicron COVID-19 Variant
Sep 23, 2021
Regeneron Welcomes World Health Organization Recommendation for Use of REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
May 17, 2021
Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Apr 09, 2021
Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission
Feb 01, 2021
EMA Commences Rolling Review of Regeneron’s COVID-19 Antibody Cocktail
Jan 02, 2021
Regeneron Statement on Preliminary Injunction of the Most Favored Nation Rule
Dec 28, 2020
Regeneron Letter to Ophthalmology Community Regarding the Most Favored Nation Interim Final Rule
Dec 14, 2020
Regeneron Provides Update on Odronextamab Clinical Trials in B-cell Non-Hodgkin Lymphomas
Dec 11, 2020
Regeneron Statement on Most Favored Nation Interim Final Rule Lawsuit
Nov 05, 2020
RECOVERY Trial Data Monitoring Committee Recommends Continuing Evaluation of REGN-COV2 in All Hospitalized Patients
Oct 31, 2020
Regeneron Announces Presentation of Additional REGN-COV2 COVID-19 Outpatient Trial Results at the 20th Annual Meeting of the Federation of Clinical Immunology Societies
Oct 30, 2020
Regeneron Provides Update on the Garetosmab Phase 2 LUMINA-1 Trial in Fibrodysplasia Ossificans Progressiva (FOP)
Oct 07, 2020
Statement on REGN-COV2 Emergency Use Authorization Request
Oct 02, 2020
Regeneron Confirms that REGN-COV2 Antibody Cocktail Provided to President Trump Under Compassionate Use Request
Aug 18, 2020
Regeneron provides update on fasinumab program
Jun 24, 2020
Statement Regarding U.K. Supreme Court Decision on Two VelocImmune® European Patents
Feb 06, 2020
Regeneron Announces Departure of Jay S. Markowitz, M.D., Senior Vice President of Portfolio Management
Sep 06, 2019
U.S. Court Dismisses Novartis Patent Infringement Suit Against Regeneron
Jul 19, 2019
Statement Regarding Praluent® (alirocumab) in Germany
Jul 11, 2019
Statement Regarding Düsseldorf Regional Court Decision in Ongoing Praluent® (alirocumab) Patent Litigation in Germany
Nov 30, 2018
Statement Regarding Decision of Opposition Division of the European Patent Office Regarding Amgen Patent Targeting PCSK9
Aug 07, 2018
Statement Regarding New CMS Guidance for Part B Drugs
Mar 19, 2018
Statement Regarding Novartis Complaint on '688 Patent
Feb 28, 2018
Regeneron Letter to Healthcare Professionals Re: EYLEA (aflibercept) Injection
Jun 23, 2017
Regeneron Announces Departure of Michael Aberman, M.D., Senior Vice President of Strategy and Investor Relations
Jun 22, 2017